Class 3 Medicines Recall: Norgine Limited, MOVICOL Plain 13.7g powder for oral solution, EL(26)A/41
Read and act on the official notice on GOV.UK
The defect is unlikely to cause harm to the patient.
What all four recall classes mean
| Class | Action | The MHRA's definition |
|---|---|---|
| Class 1 | Immediate action | The defect presents a risk of death or disability. |
| Class 2 | Action within 48 hours | The defect may cause mistreatment or harm to the patient, but it is not life-threatening or serious. |
| Class 3 this recall | Action within 5 days | The defect is unlikely to cause harm to the patient. |
| Class 4 | Caution in use | Usually minor defects in packaging or other printed materials. |
A Class 1 recall usually comes with a National Patient Safety Alert. Source: MHRA, safety communications.
In plain English, for the pharmacy team
Why is this relevant to community pharmacy
MOVICOL Plain is a laxative powder for oral solution. Norgine says some units in the listed batches may have the wrong amounts of active ingredients. This affects stock in pharmacy and any packs supplied to patients.
What to tell patients
Use your professional judgement for each patient.
- No further action is required.
- If you already have this medicine, you may continue to take it.
- If you have any side effects or questions about the medicine, seek medical attention.
- Any suspected side effects should be reported via the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card scheme.
What needs to be done
- Stop supplying the batches listed in the notice straight away.
- Quarantine all remaining stock of the listed batches.
- Return the quarantined stock to your supplier using your supplier’s approved process.
- Pharmacists: be aware patients who already have this product may continue to take it.
- Pharmacists: report any suspected adverse reactions via the MHRA Yellow Card scheme.
- Read and act on the official GOV.UK notice.
Pharmshark summary, checked and approved by Chris Dotchin on 1 Nov 2026. It is not the official notice: always read and act on the GOV.UK notice.
How this summary was written
An AI tool drafted it from the MHRA's own notice and nothing else. A second check compared every line with the notice. Pharmshark's clinical lead then read it against the notice, edited it where needed and approved it. If the MHRA changes the notice, this summary is taken down until it has been checked again.
The MHRA's summary
Norgine Limited is recalling specific batches of product as a precautionary measure due to some units containing the incorrect amounts of active ingredients.
Affected batches
As listed by the MHRA, exactly as published. Always check against the GOV.UK notice before acting.
| Batch number | Expiry | Pack size | First distributed |
|---|---|---|---|
| MOVICOL Plain 13.7g powder for oral solution | |||
| 487069 | 28/02/2029 | 30 | 05/06/2026 |
| 474919 | 31/08/2028 | 30 | 07/11/2025 |
MHRA's audience tags: Dispensing GP practices, Pharmacy